Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
Gyroscope Therapeutics is a clinical-stage gene therapy company focused on developing therapies and treating diseases of the eye.
Kynexis is advancing the first potential precision medicine for the treatment of cognitive impairment associated with schizophrenia (CIAS).
Braveheart Bio is a clinical-stage biotechnology company focused on developing precision therapies in the cardiovascular disease space.
AAVantgarde Bio is a clinical-stage biotechnology company that develops gene therapies for inherited retinal disorders.
Gate Bioscience is a biotechnology company that specializes in a small molecule modality to treat biology’s intractable diseases.
SynOx Therapeutics is a biotechnology research company that focused on developing the treatment of diffuse tenosynovial giant cell tumors.
Aiolos Bio is a biotech company developing innovative therapies for respiratory diseases and immune conditions.
Tessellate BIO is a biotechnology business in the preclinical stage that focuses on advanced Synthetic Lethality techniques.
Inversago Pharma is a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists
Rectify Pharmaceuticals is a biotechnology company developing Positive Functional Modulators (PFMs), disease-modifying therapeutics.
VectivBio is a biotechnology company committed to making innovative treatments for patients suffering from serious rare diseases.
Mestag Therapeutics is a biotechnology company that develops new therapies for diseases using fibroblast technology.
Tropic Biosciences is a pioneering leader in the development of novel high-performing commercial tropical crop varieties and traits.
Slate Medicines develops therapeutics that target Pituitary Adenylate Cyclase-Activating Polypeptide for migraine treatment and prevention.
Altesa is a clinical-stage biopharmaceutical company dedicated to accelerating the development of new treatments
Beacon Therapeutics is a biotechnology company that develops treatments to preserve and restore vision for rare and prevalent eye diseases.
Corsera Health develops preventive RNA interference medicines that reduces cardiovascular disease risk before long-term damage occurs.
Dyne Therapeutics is a developer of targeted therapies intended for serious muscle diseases.
Sidera Bio harness human genetics, that helps in transformative medicines for patients.
Crescent Biopharma is a biotechnology firm focused on developing novel precision-engineered medicines.
PACT designs Elegant materials produced in tune with the planet earth.
Elevara is a clinical-stage firm working on innovative therapies to treat rheumatoid arthritis and other chronic inflammatory disorders.
Expedition Therapeutics is a biotechnology company that develops novel therapies for inflammatory and respiratory diseases.
Mosanna Therapeutics develops a nasal spray for treating obstructive sleep apnea.
Forbion Capital Partners has invested in 122 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Forbion Capital Partners's top investment sectors include Biotechnology, Therapeutics, Health Care, Medical, Life Science. The firm invests across 16 different industry categories.
Among tracked funding rounds, Dyne Therapeutics received $402.5M in a Post Ipo Equity round. Forbion Capital Partners's total known invested capital is $9.0B.
Forbion Capital Partners's average investment size is $95.7M across its portfolio of 122 companies.
Recent Forbion Capital Partners portfolio additions include Gyroscope Therapeutics, Kynexis, Braveheart Bio, AAVantgarde Bio, Gate Bioscience. These companies were founded in 2020 or later.